Buying Guides

Ruxolitinib Cream Vitiligo Buy Online: Opzelura/Lumirix | GLT

If your search is ruxolitinib cream vitiligo buy online, you are looking for the first and only topical JAK inhibitor approved to repigment non-segmental vitiligo — sold as Opzelura in the United States and Europe, and as Lumirix (百卢妥) in China and Southeast Asia. GLT supplies the Lumirix (Ruxolitinib) 1.5% cream 100g, an NMPA-approved topical treatment for both vitiligo and atopic dermatitis (AD), at an indicative price of around $800 for a 100g tube.

What Is a JAK Inhibitor Cream?

Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors, which work by blocking the JAK–STAT signaling pathway that drives inflammation. The oral forms of ruxolitinib are used for blood disorders such as myelofibrosis, but the cream formulation delivers the same molecule directly to the skin. This topical form limits systemic exposure while still interrupting the inflammatory signals that destroy melanocytes in vitiligo and inflame the skin in atopic dermatitis.

When you search "jak inhibitor cream buy," the product you are most likely trying to find is exactly this: a topical JAK inhibitor cream. Ruxolitinib cream is the first-in-class topical JAK inhibitor, and it remains the reference point for the category. Because it is a prescription medicine, buying it is handled through an inquiry process rather than a self-service cart — more on that below.

Ruxolitinib Cream for Vitiligo: How Repigmentation Works

Vitiligo is a chronic autoimmune condition in which the body's immune system attacks melanocytes, the cells that produce skin pigment. The result is the loss of color in patches of skin, most visibly on the face and neck. Historically, dermatologists relied on corticosteroids, calcineurin inhibitors and phototherapy, none of which directly target the underlying mechanism. Ruxolitinib cream changed that by locally blocking JAK1/JAK2 signaling, creating an environment in which melanocytes can recover and repigment the skin.

The pivotal evidence comes from two identical Phase 3 trials, TRuE-V1 and TRuE-V2. At week 24, 29.9% of patients achieved at least a 75% improvement in the facial vitiligo area scoring index (F-VASI75), compared with just 7.5% and 12.9% in the placebo groups. Repigmentation continued to build through 52 weeks. In China, the approval indication is for non-segmental vitiligo with facial involvement in adults and children aged 12 and older — the China label is specifically restricted to facial involvement, so treatment should follow the local prescribing information.

Ruxolitinib Cream for Atopic Dermatitis (AD)

The same 1.5% cream is also approved for mild-to-moderate atopic dermatitis, the chronic inflammatory skin condition commonly known as eczema. In the United States, the indication covers adults and children aged 2 and older whose disease is not well controlled with topical prescription therapies, or for whom those therapies are not recommended. In China, the atopic dermatitis indication was added in September 2026, following the initial vitiligo approval in January 2026.

In a Chinese Phase 3 study, ruxolitinib cream met its primary endpoint: at week 8, 63% of patients achieved clear or almost-clear skin (IGA 0/1) with at least a 2-grade improvement, versus 9.2% on placebo. The EASI-75 response rate was 78% in the active arm versus 15.4% on placebo, with no treatment discontinuations due to adverse events. This makes it a targeted option for patients who want a non-steroid topical for long-term management of sensitive areas like the face.

Lumirix Cream vs Opzelura: One Molecule, Two Brand Names

One of the most common points of confusion is the relationship between Lumirix and Opzelura, since both appear alongside "ruxolitinib cream." The facts are straightforward:

  • Opzelura is the originator brand, developed and marketed by Incyte in the United States and Europe.
  • Lumirix (百卢妥) is the brand used in China, Hong Kong, Macao, Taiwan and Southeast Asia, commercialized by China Medical System (CMS) under license from Incyte.
  • Both contain the same active ingredient: ruxolitinib phosphate 1.5%, and both are supplied in 100g tubes (the US version is also available in 60g).

So when you search "lumirix cream", you are looking at the China/Asia presentation of the same medicine sold as Opzelura in the West. The only real difference is the regional brand label and, for the China version, the NMPA approval number 国药准字HJ20260018. You can review the official US prescribing information on the DailyMed entry for ruxolitinib cream and on the Opzelura product site.

Lumirix Ruxolitinib Cream Price

If your search is "lumirix ruxolitinib cream price," the short answer is that the China-origin product is materially more affordable than the Western retail price. GLT's indicative price for the Lumirix (Ruxolitinib) 1.5% cream 100g is around $800 per 100g tube. For reference, the originator cream in mainland China retails for roughly 5,800–6,800 RMB per 100g tube, so sourcing the China-Mainland presentation through GLT reflects that regional pricing rather than US list pricing.

The US-market Opzelura (Ruxolitinib) cream is available in 60g and 100g tubes on a quote basis — contact us for current availability. Because both versions are prescription medicines, final pricing is confirmed at inquiry along with batch details and expiry.

How to Apply Ruxolitinib Cream and What to Watch For

Ruxolitinib cream is applied as a thin layer twice daily, with at least 12 hours between applications. The amount and area you treat depend on the condition. For atopic dermatitis, the US label allows application to affected areas of up to 20% of body surface area, capped at one 60g tube per week or one 100g tube per two weeks. For non-segmental vitiligo, the limit is up to 10% of body surface area with the same tube-use caps. The China label, for its part, advises a total use of no more than 200g per month, applied only to affected skin while avoiding the eyes, mouth, nose and other mucosal areas.

Because it is a topical JAK inhibitor, ruxolitinib cream has far lower systemic exposure than the oral form, but the same class-level boxed warning still applies and should not be ignored. Serious infections, malignancies, major cardiovascular events and blood clots have been seen with oral JAK inhibitors, and these risks are stated on the topical label as well. In practice, the most common side effects of the cream are local — application-site folliculitis, irritation, nasopharyngitis and headache, most of which are mild and resolve on their own. Avoid use during an active serious infection, and tell your dermatologist about any history of cancer, heart disease, clotting disorders or recurrent infections before starting. Patients should also protect treated skin from excessive sun exposure.

Where to Buy Ruxolitinib Cream Online

Ruxolitinib cream is a prescription medicine, so GLT follows an inquiry process rather than a self-service cart. If your search is "ruxolitinib cream buy online," here is how sourcing works:

  1. Confirm the indication — vitiligo or atopic dermatitis — and whether the China label (facial vitiligo) or US label applies to your situation, with your dermatologist.
  2. Send your inquiry via WhatsApp or email with the strength (1.5%), tube size (100g) and quantity you need.
  3. Our team verifies availability, batch and expiry, then arranges dispatch with appropriate storage.

For a fuller picture of the same molecule in its oral form, see our ruxolitinib (Jakafi/Jakavi) buying guide, and browse our other buying guides for related dermatology and specialty medicines.

Questions or ready to order? Contact us on WhatsApp +86 15234153837 or email [email protected].

Frequently Asked Questions

What is ruxolitinib cream used for?

Ruxolitinib 1.5% cream is a topical JAK1/JAK2 inhibitor used to treat non-segmental vitiligo (facial involvement in the China label) and mild-to-moderate atopic dermatitis. It works by blocking the inflammatory signals that destroy pigment cells and inflame the skin.

Is Lumirix the same as Opzelura?

Yes. Both contain ruxolitinib phosphate 1.5%. Opzelura is the Incyte brand in the US and Europe, while Lumirix (百卢妥) is the brand in China, Hong Kong, Macao, Taiwan and Southeast Asia, commercialized by CMS under license from Incyte.

How much does Lumirix ruxolitinib cream cost?

GLT's indicative price for Lumirix 1.5% cream 100g is around $800 per tube. The Opzelura US version is available on a quote basis. Contact us for a current quote for your tube size and quantity.

Is ruxolitinib cream approved in China?

Yes. It was approved by China's NMPA in January 2026 as the first topical JAK inhibitor for vitiligo, and gained an additional approval for mild-to-moderate atopic dermatitis in September 2026.

How is ruxolitinib cream applied?

It is applied twice daily as a thin layer to the affected areas, with at least 12 hours between applications. The China label caps total use at 200g per month. Always follow your dermatologist's instructions.

Do I need a prescription to buy ruxolitinib cream online?

Ruxolitinib cream is a prescription medicine. GLT's inquiry process includes verification before dispatch — contact us via WhatsApp or email, and our team will guide you through what is required.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Ruxolitinib cream (Opzelura/Lumirix) is a prescription medicine; always consult a qualified dermatologist or healthcare professional about diagnosis, dosage and treatment. Prices are indicative and subject to confirmation at inquiry.

Regorafenib Buy Stivarga: Bayer 40mg Buying Guide | GLT
Ruxolitinib Buy Online: Jakafi/Jakavi 5mg Tablets | GLT